US Patent

US8461330 — Imidazotriazines and imidazopyrimidines as kinase inhibitors

Composition of Matter · Assigned to Incyte Corp · Expires 2027-11-19 · 2y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, which are kinase inhibitors useful in treating cancer and other diseases.

USPTO Abstract

The present invention is directed to imidazo[1,2-b][1,2,4]triazines and imidazo[1,2-a]pyrimidines, and pharmaceutical compositions thereof, which are inhibitors of kinases such as c-Met and are useful in the treatment of cancer and other diseases related to the dysregulation of kinase pathways.

Drugs covered by this patent

Patent Metadata

Patent number
US8461330
Jurisdiction
US
Classification
Composition of Matter
Expires
2027-11-19
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Incyte Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.